Mucosal Healing and anti TNFs in IBD

Author(s): Gert van Assche , Severine Vermeire , Paul Rutgeerts .

Journal Name: Current Drug Targets

Volume 11 , Issue 2 , 2010

Become EABM
Become Reviewer


Mucosal healing has been incorporated in the assessment of treatment efficacy in ulcerative colitis, but in Crohns disease this concept has only emerged after biological therapies have been evaluated in clinical trials. Systemic steroids dont induce mucosal healing in Crohns disease, but purine analoges and anti TNF agents have a potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti TNF agents infliximab, adalimumab and certolizumab. For infliximab mucosal healing is associated with a reduction in hospitalizations and surgeries. On the contrary, the benefit of treating patients with IBD more intensively until they achieve mucosal healing has not been proven. In clinical practice assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy and when treatment discontinuation is being considered.

Keywords: Mucosal healing, endoscopy, medical therapy, IBD, Crohn's disease, ulcerative colitis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [227 - 233]
Pages: 7
DOI: 10.2174/138945010790309902
Price: $58

Article Metrics

PDF: 12